regulatory
confidence high
sentiment neutral
materiality 0.30
Bioventus Exogen device reclassified by FDA, CMS updates reimbursement rates; company reiterates 2026 guidance
Bioventus Inc.
- FDA reclassified non-invasive bone growth stimulators, including Bioventus' Exogen Ultrasound Bone Healing System, from Class III to Class II on April 16, 2026.
- CMS updated Medicare fee schedule for HCPCS codes E0747, E0748, and E0760 for services on or after May 18, 2026.
- Bioventus does not expect material impact from reimbursement rate changes on its FY2026 financial results.
- Company reiterates previously issued 2026 financial guidance despite the regulatory changes.
- Bioventus continues to evaluate long-term impact; future CMS actions could require revised outlook.